title: Do Statins Reduce the Health and Health Care Costs of Obesity?
abstract: BACKGROUND
  Obesity impacts both individual health and, given its high prevalence, total health care spending. However, as medical technology evolves, health outcomes for a number of obesity-related illnesses improve. This article examines whether medical innovation can mitigate the adverse health and spending associated with obesity, using statins as a case study. Because of the relationship between obesity and hypercholesterolaemia, statins play an important role in the medical management of obese individuals and the prevention of costly obesity-related sequelae.
  
  
  METHODS
  Using well-recognized estimates of the health impact of statins and the Future Elderly Model (FEM)-an established dynamic microsimulation model of the health of Americans aged over 50 years-we estimate the changes in life expectancy, functional status and health care costs of obesity due to the introduction and widespread use of statins.
  
  
  RESULTS
  Life expectancy gains of statins are estimated to be 5-6 % greater for obese individuals than for healthy-weight individuals, but most of these additional gains are associated with some level of disability. Considering both medical spending and the value of quality-adjusted life-years, statins do not significantly alter the costs of class 1 and 2 obesity (body mass index [BMI] ≥30 and ≥35 kg/m(2), respectively) and they increase the costs of class 3 obesity (BMI ≥40 kg/m(2)) by 1.2 %.
  
  
  CONCLUSIONS
  Although statins are very effective medications for lowering the risk of obesity-associated illnesses, they do not significantly reduce the costs of obesity.
authors.affiliation: Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Suite 210, Los Angeles, California, 90089-3333, USA, egaudett@healthpolicy.usc.edu.
authors.forename: Étienne
authors.initials: É
authors.lastname: Gaudette
authors.forename: Dana P
authors.initials: DP
authors.lastname: Goldman
authors.forename: Andrew
authors.initials: A
authors.lastname: Messali
authors.forename: Neeraj
authors.initials: N
authors.lastname: Sood
mesh_terms: D000368:Aged; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D017048:Health Care Costs / Q000706:statistics & numerical data / Q000639:trends*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D008017:Life Expectancy; D008390:Markov Chains; D018803:Models, Economic; D009765:Obesity / Q000188:drug therapy / Q000191:economics*; D019057:Quality-Adjusted Life Years
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors